Registered number | |
|
|
||
Amended Unaudited Accounts | ||
for the year ended | ||
|
||
Balance Sheet as at |
|||||
---|---|---|---|---|---|
Notes |
2024 £ |
2023 £ |
|||
Creditors: amounts falling due within one year | ( |
( |
|||
Net current assets / (liabilities) | ( |
( |
|||
Total assets less current liabilities | ( |
( |
|||
Provisions for liabilities | ( |
( |
|||
Total net assets (liabilities) | ( |
( |
|||
Capital and reserves | |||||
Called up share capital | 2 |
|
|
||
Other reserves |
|
|
|||
Profit and loss account | ( |
( |
|||
Shareholders' funds | ( |
( |
Balance Sheet
as at
The directors have not delivered a copy of the company's Profit and Loss account as permitted by s444(5A) of the Companies Act 2006.
Signed on behalf of the board of directors
...............................
Mr. K Look
Director
Approved by the board on
Company Number: 07645726 (a Private Company Limited by Shares registered in England and Wales)
Registered Office:
C/o Mccarthy Tetrault 1 Angel Court
Notes to the Accounts
for the year ended
1. | Accounting policies |
---|---|
Basis of preparation of financial statements |
2. | Share capital | |||
---|---|---|---|---|
2024 | 2023 | |||
£ | £ | |||
Allotted, called up and fully paid: | ||||
|
100 | 100 | ||
100 | 100 |
Related party disclosures | ||
---|---|---|
During the period of accounts a transaction occurred between this company and a related party, Oncolytics Biotech Inc.. The relationship between the parties is Ultimate Parent. At the balance sheet date the related party owed the company £226,472 (2023 - £226,272). During the period of accounts a transaction occurred between this company and a related party, Oncolytics Biotech (Barbados) Inc Inc. The relationship between the parties is Parent. At the balance sheet date the related party owed the company £16,892 (2023 - £16,892). |
||
Controlling party Controlling party Amounts due to and from related parties are interest free, unsecured and payable on demand. The transactions were entered in the ordinary course of business. a.) Parent entities The Company is a 100% subsidiary undertaking of Oncolytics Biotech (Barbados) Inc., which is a 100% subsidiary of Oncolytics Biotech Inc. |
4. | Other information |
---|---|
Share based payment reserve |